

# The predictive power of depression screening procedures for veterans with coronary artery disease

Stewart A Shankman<sup>1\*</sup>  
Jeffrey Nadelson<sup>2\*</sup>  
Sarah Kate McGowan<sup>1</sup>  
Ali A Sovari<sup>2</sup>  
Mladen I Vidovich<sup>2</sup>

<sup>1</sup>Department of Psychiatry and Psychology, University of Illinois,

<sup>2</sup>Department of Cardiology, Jesse Brown VA Medical Center, Chicago, IL, USA

\*These authors contributed equally to this work

**Abstract:** Depression leads to a worse outcome for patients with coronary artery disease (CAD). Thus, accurately identifying depression in CAD patients is imperative. In many veterans affairs (VA) hospitals, patients are screened for depression once a year using the patient health questionnaire (PHQ-9). Although the PHQ-9 is generally considered a specific and sensitive measure of depression, there is reason to believe that these screening procedures may miss a large number of cases of depression within CAD patients and cardiology patients more generally. The goal of this study was to provide data as to the predictive power of this depression screening procedure by (a) comparing the prevalence rate of depression identified by the PHQ-9 to known prevalence rates and (b) examining whether patients identified as “depressed” also had conditions that consistently co-occur with depression (eg, post-traumatic stress disorder [PTSD], other medical issues). Participants were 813 consecutive patients who received an angiogram in the cardiac catheterization laboratory at a large VA Medical Center. Prevalence of depression was 6.9% in the overall sample and less than 6% when the sample was restricted to CAD patients with significant stenosis. Depression was significantly associated with PTSD, smoking, and alcohol problems. However, depression was not associated with other medical problems such as diabetes, renal failure, peripheral vascular disease, or anemia. In conclusion, the low prevalence rate of depression and lack of associations with comorbid medical problems may suggest that the VA’s depression screening procedures have low sensitivity for identifying depression in CAD patients. It is recommended that clinicians treating CAD regularly screen for depression and do not rely on archival depression screens.

**Keywords:** depression screening, coronary artery disease, PHQ-9, veterans

## Introduction

Studies have consistently demonstrated that the prognosis, outcome, and treatment adherence for coronary artery disease (CAD) patients with comorbid major depressive disorder (MDD) is worse than in those without MDD.<sup>1-4</sup> Thus, accurate identification of MDD in CAD patients is critical.<sup>5,6</sup> Many hospitals (including most Veteran’s Affairs [VA] hospitals) screen for depression annually using the Patient Health Questionnaire (PHQ-9), a questionnaire which assesses for depressive symptoms over the previous two weeks.<sup>7-9</sup> While the PHQ-9 has demonstrated adequate validity at correctly identifying patients with MDD, screening for depression annually may miss a large number of cases (ie, false negatives) as the episodes of MDD may not correspond with the timing of the screening.

The goal of this study is therefore to provide data regarding the predictive power of annual depression screening in CAD patients and patients who underwent

Correspondence: Mladen Vidovich  
Section of Cardiology, Jesse Brown VA  
Medical Center, Assistant Professor of  
Medicine, University of Illinois at Chicago,  
840 S Wood St, MC 715, Chicago,  
IL 60612, USA

Tel +1 312 996 6730

Fax +1 312 413 2948

Email miv@uic.edu

catheterization procedures more generally. First, we examined whether the prevalence rate is consistent with the known prevalence rate of depression. Second, given that numerous studies have shown that depression is highly comorbid with post-traumatic stress disorder (PTSD),<sup>10,11</sup> substance use disorders,<sup>11,12</sup> and several chronic medical diseases and CAD risk factors (diabetes,<sup>13</sup> renal failure,<sup>14</sup> peripheral vascular disease (PVD),<sup>15</sup> anemia,<sup>16</sup> and hypertension),<sup>17</sup> we examined whether individuals with MDD (as assessed by the PHQ-9) exhibited the expected high rate of co-occurrence of these conditions.

## Methods

### Participants

Participants included all consecutive patients (N = 1087) from June 1, 2008 through June 1, 2010 who underwent cardiac catheterization at the Jesse Brown VA Medical Center (Chicago, IL). Indications for cardiac catheterization followed standard practices in the United States. Specifically, patients were referred for coronary angiography after they were evaluated by a cardiologist and the procedure was indicated for them based on their clinical presentation and results of diagnostic tests such as electrocardiography, echocardiography, stress testing and Holter monitoring. Indications for coronary angiography included acute myocardial infarction, hemodynamic instability with or without cardiogenic shock, severe left ventricular dysfunction or overt heart failure, recurrent or persistent rest angina (despite intensive medical therapy), mechanical complications (such as acute mitral regurgitation or ventricular septal defect), sustained ventricular tachycardia, inconclusive or conflicting results after noninvasive stress testing, patient's ability to undergo noninvasive testing (disability, illness, or morbid obesity), or reevaluation of performed procedures (main stem percutaneous coronary intervention [PCI], high stenosis risk).

The inclusion/exclusion criteria were very broad. Given the low prevalence of women in this sample (N = 28; a number which is consistent with the population of veterans in this age range), the sample was restricted to male veterans. An additional 246 veterans were excluded because they did not complete a patient health questionnaire (PHQ-9) within a year of the visit to the catheterization laboratory. Thus, excluding these participants yielded a final N = 813. This investigation was approved by the institutional review boards (IRB) at the Jesse Brown VA Medical Center and the University of Illinois at Chicago and participants gave informed consent to have their medical records used for this research.

## Measures

### Medical variables

All coronary angiography reports were reviewed and the maximum percentage of stenosis was recorded for each patient. Revascularization procedures – coronary angioplasty (PCI), referral for coronary artery bypass surgery (CABG) – were recorded as well.

### Depression assessment (PHQ-9)

The PHQ-9 is a nine item self-report questionnaire in which respondents rate the presence of the 9 core symptoms of a major depressive episode over the preceding two weeks. Each question is scored on a 4-point score where: 0 = not at all, 1 = several days, 2 = more than half the days, and 3 = nearly every day. Although the PHQ-9 has been used as continuous measure of depression, in most medical settings, the general convention is to determine cases of MDD with a cutoff of  $\geq 10$ .<sup>8,9,18</sup> Additionally, the PHQ-9 has been shown to be highly correlated with other validated measures of depression (eg,  $r = 0.73$  with the Beck depression inventory [BDI]).<sup>19</sup>

### Other psychiatric and substance use variables

#### PTSD

The primary care-PTSD screen<sup>20</sup> (PC-PTSD) is a 4-item self-report measure used to identify individuals with PTSD or trauma-related problems. The PC-PTSD asks patients to recall a traumatic event and indicate whether or not, over the past month, they experienced any of four symptoms related to the four core factors of PTSD.<sup>21</sup> Presence of at least three symptoms identifies veterans with PTSD with strong sensitivity (0.85) and specificity (0.82).<sup>20,22</sup>

#### Alcohol use disorders

The alcohol use disorders identification test<sup>23</sup> (AUDIT-C) is a 3-item self-report measure used to identify individuals with alcohol abuse or dependence. Scores range from 0–12 and a cutoff  $\geq 4$  identifies male veterans who drink heavily and/or have active alcohol abuse or dependence with a sensitivity of (0.86) and a specificity of (0.72).<sup>23,24</sup>

Of note is that the above cutoffs for the PC-PTSD and AUDIT are the ones adopted by the VA<sup>25,26</sup> for determining referral or follow-up treatment for PTSD and alcohol problems, respectively. From patient's medical records, we also recorded whether they reported smoking on a regular basis.

The PHQ-9, PTSD, and AUDIT-C screens are given annually to patients at most VA hospitals and the most recent

assessment prior to the patients' cardiac catheterization was selected for analysis.

## Data analysis

All analyses were performed using SPSS (v 16.0; SPSS Inc, Chicago, IL). *T*-tests and chi-squared tests were used for group comparisons on demographics. Logistic regressions (adjusted for covariates) were used to examine the association between depression status and the psychiatric, substance and medical issues.

## Results

### Descriptive statistics and angiography

The sample had a mean age of  $64.6 \pm 10.8$  years, body mass index (BMI) of  $29.6 \pm 6.4$ , and was ethnically diverse, although the majority of the sample was African-American: 63.1% African-American, 32.8% White, 3.2% Hispanic and 0.9% other ethnicity.

Normal coronaries were present in 24.1% of patients, 19.5% had between 1 and 50% stenosis, 7.6% had between 51% and 70% stenosis, 24.5% had between 71% and 99% stenosis, and 24.3% had 100% stenosis in one of the major coronary arteries. PCI was performed in 24.7% of the sample and an additional 10.7% were referred for CABG. The other 64.6% of the sample received standard medical management for CAD.

### Prevalence of depression

Of the 813 veterans who underwent catheterization procedures, only 56 scored  $\geq 10$  suggesting a prevalence of 6.9%.

If the sample was restricted to veterans with more than 50% stenosis ( $N = 454$ ), the prevalence was 5.9%. If the sample was restricted to more than 70% stenosis ( $N = 393$ ), the prevalence was 5.6%. Thus, the estimated prevalence rate of depression was largely consistent whether all patients were examined or just patients with significant stenosis.

Additionally, in the overall sample, 640 (78.7%) scored a 0 on the PHQ-9 (slightly larger percentages were observed in veterans with significant stenosis). Given the highly skewed nature of depressive symptoms in the present sample, for all subsequent analyses, we compared those who scored 0 to those who scored above 10 (thus, excluding those who endorsed a few symptoms of depression, but fell below the clinically significant range). Compared to those who endorsed zero symptoms, veterans in the clinical range on the PHQ-9 were significantly younger (55.8 versus 65.8,  $P < 0.001$ ; adjusted for significant Levene's Test) and had higher BMI (31.9 versus 29.2;  $P < 0.01$ ), with no ethnic differences.

Age and BMI were therefore included as covariates in the analyses below.

In order to examine whether the results varied by whether patients had significant stenosis (ie, true CAD patients), analyses were also conducted in those with (a) greater than 50% stenosis, and (b) greater than 70% stenosis. It is noteworthy that depression was not related to degree of stenosis ( $r = -0.05$ , ns).

### Association between depression and substance and psychiatric problems

The top of Table 1 presents results examining the co-occurrence of depression and several substance and psychiatric problems. After adjusting for age and BMI, smoking, alcohol, and PTSD were all significantly related to depression status on the PHQ-9 in the overall sample and in patients with significant stenosis.

### Association with medical comorbidities/CAD risk factors

The bottom of Table 1 presents the results examining the co-occurrence of depression and several medical issues and risk factors for CAD. Individuals with depression did not have a significantly greater likelihood of having diabetes, renal failure, peripheral vascular disease, and anemia. Individuals with depression had a marginally higher likelihood of hypertension in the overall sample.

## Discussion

This study examined the predictive power of the PHQ-9 in male veterans receiving cardiac catheterization. Given the importance of depression to the course and outcome of CAD,<sup>1,2</sup> it is important that valid procedures for screening depression are in place. This is particularly true for veterans, a population for whom CAD is quite prevalent.<sup>10</sup> Our study had several noteworthy findings.

In the overall sample, only 56 veterans scored in the clinical range on the PHQ-9 suggesting a prevalence of 6.9%. Similar (and even somewhat lower) rates were observed if the analyses were restricted to true CAD patients with significant stenosis ( $>50\%$  or  $>70\%$  blockage). Although the true prevalence of MDD in veterans with CAD is unknown, this number is considerably lower than what the literature would suggest. Studies in CAD patients suggest that the prevalence of MDD in patients with CAD in the general population is approximately 20%–23%.<sup>27,28</sup> Additionally, one would predict that this number would likely be higher in veterans given the increased rates of depression in veterans

**Table 1** Association between PHQ-9 assessed depression and conditions known to be associated with depression

	% of total sample	Association with PHQ-9 depression Odds ratio (OR), 95% CI		
		Total sample	Sample with >50% stenosis	Sample with >70% stenosis
Psychiatric and substance use disorders				
PTSD	9.5%	4.01 (1.98–8.13)***	2.91 (1.08–7.90)*	4.43 (1.53–12.82)**
Smoking	25.7%	2.22 (1.22–4.04)**	4.82 (2.00–11.615)***	5.17 (1.91–13.97)**
Alcohol	10.7%	2.62 (1.29–5.30)**	2.86 (1.00–8.21)*	3.08 (0.96–9.93) <sup>†</sup>
Medical issue/CAD risk factor				
Diabetes	41.3%	ns	ns	ns
Renal failure	26.8%	ns	ns	ns
Peripheral vascular disease	17.7%	ns	ns	ns
Anemia	12.6%	ns	ns	ns
Hypertension	87.7%	4.01 (0.94–17.07) <sup>†</sup>	ns <sup>a</sup>	ns <sup>a</sup>

**Notes:** All OR are adjusted for age and BMI. \* $P \leq 0.05$ ; \*\* $P \leq 0.01$ ; \*\*\* $P \leq 0.001$ ; <sup>†</sup> $P < 0.10$ ; <sup>a</sup>For patients with substantial stenosis, although non-significant, the confidence intervals for odds ratios could not be calculated for hypertension because every patient with depression (N = 27 in Veterans with >50% stenosis and N = 22 in veterans with >70% stenosis) had hypertension (and, conversely, no patient without hypertension had depression).

**Abbreviations:** BMI, body mass index; CI, confidence interval; CAD, coronary artery disease; ns, not-significant; OR, odds ratio; PTSD, post-traumatic stress disorder.

compared to the general population.<sup>29</sup> There are several possible explanations for this low prevalence rate.

First, it is possible that the PHQ-9 is uniformly invalid at assessing depression in veteran males with CAD. This conclusion, however, would be inconsistent with the overall strong predictive power exhibited by the PHQ-9 in other populations (including veterans).<sup>8,9</sup> Additionally, this conclusion would be inconsistent with the fact that depression was significantly associated with comorbid mental health conditions. Numerous studies have shown that depression frequently co-occurs with PTSD, alcohol use disorders, and smoking problems.<sup>10–12</sup> Thus, the fact that depression was associated with the mental health conditions in the present study suggests that PHQ-9 appeared to largely identify valid cases of depression.

An alternative and more likely reason for the low prevalence rate is that the PHQ-9 likely identified individuals with MDD (ie, low number of “false positives”) but the PHQ-9 likely missed a large number of cases as well (ie, large number of “false negatives.”). In other words, the PHQ-9 may have exhibited low sensitivity. Interestingly, our results were consistent with the Heart and Soul study, which found that the PHQ-9 may have strong specificity in CAD patients, but inadequate sensitivity in this population.<sup>27</sup> This conclusion is also supported by the present finding that depression was not significantly associated with any of the medical issues/CAD risk factors or degree of stenosis, despite a large literature suggesting that depression should be correlated with these variables. Lastly, a high number of “false negatives” is also consistent with the fact that a surprisingly high 78.7% of CAD veterans denied any symptoms of depression.

Thus, the VA's procedures for screening depression may not be adequately identifying all CAD patients who have depression. This is likely to be particularly problematic for African-American veterans (who comprised the largest percentage of our sample), a group who are not only at higher risk for CAD,<sup>30</sup> but who are also less likely to seek mental health services on their own.<sup>31,32</sup>

A concern with the VA's screening of depression may not be the screening instrument (PHQ-9), but rather the procedures under which it is administered. In most VA hospitals, the computerized personal record system flags patients who have not been administered the PHQ-9 within the last year and then reminds clinicians (typically primary care physicians) to administer it. Thus, depressive episodes that occurred closer in time to cardiac catheterization may be missed.

Additionally, the PHQ-9 is often administered by simply handing the patient the questionnaire and asking them to complete it. The validity of a self-report questionnaire assumes that individuals can read and comprehend each question. A recent study showed that the PHQ-9 requires at least a ninth grade reading level.<sup>33</sup> Hence, a subset of patients may have had difficulty reading and understanding the questions. We are currently investigating this issue by measuring the reading ability of patients who completed the PHQ-9 and examining whether this has an effect on depression prevalence.

It is important to assess for current depression when patients visit the cardiac catheterization laboratory because a depressive episode may have contributed to why patients are seeking cardiovascular care. Not only has depression been associated with both cardiac and non-cardiac chest pain,<sup>34,35</sup> but there is a growing literature on the overlapping

pathophysiology between depression and cardiac disease.<sup>36</sup> For example, inflammatory cytokines, endothelial dysfunction and autonomic nervous system dysfunction have all been proposed to play a role in both depression and cardiac disease.<sup>36-41</sup>

Additionally, it is important to assess the urgency of a patient's referral for cardiac catheterization, as severity of CAD would likely impact depression ratings. Unfortunately, in our archival database, we were unable to examine this question. However, it should be noted that the administration of the PHQ-9 was rarely the same day as the catheterization. Currently in the VA system, the PHQ-9 is only given annually and its administration does not necessarily coincide with a cardiology visit (let alone an urgent cardiology visit). Thus, it is unlikely that ratings of depression were affected by the urgency of patients' cardiac symptoms. Studies have also shown that among patients who have an urgent referral, identification of those with a psychological need is particularly predictive of outcome.<sup>42</sup> This highlights the importance of assessing depression at the time of cardiac catheterization, as well as regular screening of depression during the treatment of CAD over time.

The conclusions of the study are tempered by several limitations. First, although our sample was representative of CAD patients (and veterans in general) who receive treatment at the Jesse Brown VA, the sample was all male and predominantly African-American. Thus, our conclusions may not generalize to different populations. Second, the large percentage of patients with hypertension (87%) may have precluded us from finding a significant association between depression and this risk factor (although, it is noteworthy that this was the only medical issue/risk factor that even approached statistical significance). Third, MDD was not formally diagnosed (ie, with a diagnostic interview) in the patients. However, a formal assessment of MDD would have likely confirmed the low sensitivity of the PHQ-9 depression assessment procedures. Finally, given that we had to exclude women from the sample due to their low prevalence in the VA population, the results may not generalize to CAD patients in general, but perhaps only to male CAD patients.

In summary, our study found that the depression screening procedures employed in many VA medical centers may not be ideal as numerous cases of MDD are likely to be missed. Given the importance of depression as a predictor of prognosis and outcome in CAD, it is essential that clinicians do not solely rely on a patient's archival depression screen and regularly screen for depression in cardiology clinics. Additionally, the problems with annual self-report depression

screening highlight the importance of future research to identify valid biomarkers for depression.

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Frasure-Smith N, Lesperance F, Talajic M. Depression following myocardial infarction: Impact on 6-month survival. *JAMA*. 1993; 270(15):1819-1825.
2. Carney RM, Freedland KE, Steinmeyer B, et al. Depression and five year survival following acute myocardial infarction: A prospective study. *J Affect Disord*. 2008;109(1-2):133-138.
3. Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: Evidence, mechanisms, and treatment. *Psychosom Med*. 2004;66(3):305-315.
4. Rugulies R. Depression as a predictor for coronary heart disease: A review and meta-analysis. *Am J Prev Med*. 2002;23(1):51-61.
5. Lichtman JH, Bigger JT Jr, Blumenthal JA, et al. Depression and coronary heart disease: Recommendations for screening, referral, and treatment: A science advisory from the American Heart Association prevention committee of the council on cardiovascular nursing, council on clinical cardiology, council on epidemiology and prevention, and interdisciplinary council on quality of care and outcomes research. *Prog Cardiovasc Nurs*. 2009;24(1):19-26.
6. US Preventive Services Task Force. Screening for depression in adults: US preventive Services Task Force recommendation statement. *Ann Intern Med*. 2009;151(11):784-792.
7. United States Department of Veteran Affairs. Clinical practice guidelines-management of major depressive disorder (MDD) 2009. Available from: [http://www.healthquality.va.gov/mdd/mdd\\_full109\\_c.pdf](http://www.healthquality.va.gov/mdd/mdd_full109_c.pdf). Accessed March 8, 2012.
8. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9): 606-613.
9. Gilbody S, Richards D, Brealey S, Hewitt C. Screening for depression in medical settings with the Patient Health Questionnaire (PHQ): a diagnostic meta-analysis. *J Gen Intern Med*. 2007;22(11):1596-1602.
10. Hankin CS, Spiro A, Miller DR, Kazis L. Mental disorders and mental health treatment among US department of Veterans Affairs outpatients: The veterans' health study. *Am J Psychiatry*. 1999; 156(12):1924-1930.
11. David D, Woodward C, Esquenazi J, Mellman TA. Comparison of comorbid physical illnesses among veterans with PTSD and veterans with alcohol dependence. *Psychiatr Serv*. 2004;55(1):82-85.
12. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder - results from the national comorbidity survey replication (NCS-R). *JAMA*. 2003;289(23):3095-3105.
13. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. *Diabetes Care*. 2001;24(6):1069-1078.
14. Sumanathissa M, de Silva VA, Hanwella R. Prevalence of major depressive episode among patients with pre-dialysis chronic kidney disease. *Int J Psychiatry Med*. 2011;41(1):47-56.
15. McDermott MM, Greenland P, Guralnik JM, et al. Depressive symptoms and lower extremity functioning in men and women with peripheral arterial disease. *J Gen Intern Med*. 2003;18(6):461-467.
16. Stewart RB, Blashfield R, Hale WE, Moore MT, May FE, Marks RG. Correlates of Beck Depression Inventory scores in an ambulatory elderly population: symptoms, diseases, laboratory values, and medications. *J Fam Pract*. 1991;32(5):497-502.
17. Fiedorowicz JG, He J, Merikangas KR. The association between mood and anxiety disorders with vascular diseases and risk factors in a nationally representative sample. *J Psychosom Res*. 2011;70(2):145-154.

18. Zuihoff NPA, Vergouwe Y, King M, et al. The Patient Health Questionnaire-9 for detection of major depressive disorder in primary care: Consequences of current thresholds in a cross-sectional study. *BMC Fam Pract.* 2010;11:98.
19. Martin A, Rief W, Klaiberg A, Braehler E. Validity of the Brief Patient Health Questionnaire Mood Scale (PHQ-9) in the general population. *Gen Hosp Psychiatry.* 2006;28(1):71–77.
20. Prins A, Ouimette P, Kimerling R, et al. The primary care PTSD screen (PC-PTSD): development and operating characteristics. *Prim Care Psychiatry.* 2003;9:9–14.
21. Asmundson GJG, Frombach I, McQuaid J, Pedrelli P, Lenox R, Stein MB. Dimensionality of posttraumatic stress symptoms: A confirmatory factor analysis of DSM-IV symptom clusters and other symptom models. *Behav Res Ther.* 2000;38(2):203–214.
22. Freedy JR, Magruder KM, Mainous AG, Frueh BC, Geesey ME, Carnemolla M. Gender differences in traumatic event exposure and mental health among veteran primary care patients. *Mil Med.* 2010;175(10):750–758.
23. Bush K, Kivlahan DR, McDonnell MB, Fihn SD, Bradley KA. Ambulatory Care Quality Improvement Project. The AUDIT alcohol consumption questions (AUDIT-C) – an effective brief screening test for problem drinking. *Arch Intern Med.* 1998;158(16):1789–1795.
24. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR. AUDIT-C as a brief screen for alcohol misuse in primary care. *Alcohol Clin Exp Res.* 2007;31(7):1208–1217.
25. United States Department of Veterans Affairs. Primary care PTSD screen (PC-PTSD); 2010.
26. United States Department of Veterans Affairs. Management of substance use disorders (SUD); 2010.
27. McManus D, Pipkin SS, Whooley MA. Screening for depression in patients with coronary heart disease (data from the heart and soul study). *Am J Cardiol.* 2005;96(8):1076–1081.
28. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease – epidemiology, biology, and treatment. *Arch Gen Psychiatry.* 1998;55(7):580–592.
29. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. *N Engl J Med.* 2004;351(1):13–22.
30. National Institutes of Health. Morbidity and Mortality 2009 Chart Book on Cardiovascular, Lung and Blood Diseases 2009. Available from: [http://www.nhlbi.nih.gov/resources/docs/2009\\_ChartBook.pdf](http://www.nhlbi.nih.gov/resources/docs/2009_ChartBook.pdf). Accessed March 8, 2012.
31. Rosenheck R, Fontana A. Utilization of mental health services by minority veterans of the Vietnam era. *J Nerv Ment Dis.* 1994;182(12):685–691.
32. Schraufhagen T, Wagner A, Miranda J, Roy-Byrne P. Treating minority patients with depression and anxiety; what does the evidence tell us? *Gen Hosp Psychiatry.* 2006;28(1):27–36.
33. McHugh KR, Behar E. Readability of self-report measures of depression and anxiety. *J Consult Clin Psych.* 2009;77(6):1100–1112.
34. Eken C, Oktay C, Bacanlı A, et al. Anxiety and depressive disorders in patients presenting with chest pain to the emergency department: A comparison between cardiac and non-cardiac origin. *J Emerg Med.* 2010;39(2):144–150.
35. Srinivasan D, Yen JH, Joseph DJ, Friedman W. Cell type-specific interleukin-1 beta signaling in the CNS. *J Neurosci.* 2004;24(29):6482–6488.
36. Celano CM, Huffman JC. Depression and cardiac disease A review. *Cardiol Rev.* 2011;19(3):130–142.
37. Kania G, Blyszczuk P, Eriksson U. Mechanisms of cardiac fibrosis in inflammatory heart disease. *Trends Cardiovasc Med.* 2009;19(8):247–252.
38. Ross R. Atherosclerosis – an inflammatory disease. *N Engl J Med.* 1999;340(2):115–126.
39. Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. *Psychosom Med.* 2009;71(2):171–186.
40. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. *Biol Psychiatry.* 2009;65(9):732–741.
41. Vaccarino V, Johnson BD, Sheps DS, et al. Depression, inflammation and incident cardiovascular disease in women with suspected coronary ischemia – the national heart, lung, and blood institute-sponsored WISE study. *J Am Coll Cardiol.* 2007;50(21):2044–2050.
42. Gruen W. Effects of brief psychotherapy during the hospitalization period on the recovery process in heart attacks. *J Consult Clin Psychol.* 1975;43(2):223–232.

## Vascular Health and Risk Management

### Publish your work in this journal

Vascular Health and Risk Management is an international, peer-reviewed journal of therapeutics and risk management, focusing on concise rapid reporting of clinical studies on the processes involved in the maintenance of vascular health; the monitoring, prevention and treatment of vascular disease and its sequelae; and the involvement of

metabolic disorders, particularly diabetes. This journal is indexed on PubMed Central and MedLine. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/vascular-health-and-risk-management-journal>

Dovepress